fitusiran 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
small interfering RNA including siRNA, miRNA and piRNA 5766 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • fitusiran
  • ALN-AT3
  • SAR439774
Fitusiran is a synthetic double-stranded small interfering RNA (siRNA) conjugated to a triantennary N-acetyl galactosamine (GalNAc) ligand targeting antithrombin (AT) mRNA. Fitusiran reduces AT production in the liver by causing degradation of AT mRNA through the RNA interference pathway.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 28, 2025 FDA Sanofi

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B02BX12 BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Other systemic hemostatics
FDA CS M0406100 RNA, Small Interfering
FDA PE N0000008852 Decreased RNA Integrity
FDA EPC N0000193848 Small Interfering RNA
FDA EPC N0000194148 Antithrombin-directed RNA Interaction
FDA PE N0000194154 Increased RNA Degradation

Related Drugs by ATC class:

B02BX Other systemic hemostatics 10 drugs
avatrombopagcarbazochromeconcizumabeltrombopagemicizumabetamsylatefostamatiniblusutrombopagmarstacimab-hncqromiplostim

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Reduce the frequency of bleeding episodes in patients with hemophilia A or B indication 90935002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Antithrombin-III Secreted DRUG LABEL DRUG LABEL

External reference:

IDSource
1499251-18-1 SECONDARY_CAS_RN
CHEMBL4297754 ChEMBL_ID
C000632624 MESH_SUPPLEMENTAL_RECORD_UI
13630 IUPHAR_LIGAND_ID
DB15002 DRUGBANK_ID
4043893 VANDF
C5139801 UMLSCUI
CHEBI:757204 CHEBI
10177 INN_ID
D11810 KEGG_DRUG
43958 MMSL
d10268 MMSL
020041 NDDF
SV9W47ZLE1 UNII
2709439 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Qfitlia HUMAN PRESCRIPTION DRUG LABEL 1 58468-0347 INJECTION, SOLUTION 20 mg SUBCUTANEOUS NDA 32 sections
Qfitlia HUMAN PRESCRIPTION DRUG LABEL 1 58468-0348 INJECTION, SOLUTION 50 mg SUBCUTANEOUS NDA 32 sections